IP Library Granted Patent US 9,322,026
Granted Patent B2
US 9,322,026 · App. 13/618,693 · Granted Apr 26, 2016

Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,322,026
App. No.
13/618,693
Granted
Apr 26, 2016
Kind
B2
Abstract

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Claims (10)

1. A gene expression cassette comprising a polynucleotide that encodes a polypeptide selected from the group consisting of:

a) a polypeptide comprising a transactivation domain, a DNA-binding domain, and a Drosophila melanogaster EcR (DmEcR) ligand binding domain comprising a substitution mutation,

b) a polypeptide comprising a DNA-binding domain and a Drosophila melanogaster EcR (DmEcR) ligand binding domain comprising a substitution mutation, and

c) a polypeptide comprising a transactivation domain and a Drosophila melanogaster EcR (DmEcR) ligand binding domain comprising a substitution mutation,

wherein the DmEcR ligand binding domain is encoded by a polynucleotide comprising a codon mutation that results in a substitution at amino acid residue 107, 121, 213, or 217 of the DmEcR in SEQ ID NO: 2.

2. The gene expression cassette of claim 1 , wherein the substitution mutation is a A107P, G121R, G121L, N213A, C217A, or C217S substitution mutation of SEQ ID NO: 2.

3. The gene expression cassette of claim 1 , wherein the DmEcR ligand binding domain lacks ecdysone binding activity and the substitution mutation is at amino acid residue 107 of SEQ ID NO: 2.

4. The gene expression cassette of claim 3 , wherein the substitution mutation is a A107P substitution mutation of SEQ ID NO: 2.

5. An expression vector comprising the gene expression cassette of claim 1 operatively linked to a transcription regulatory element.

6. An isolated host cell comprising the gene expression cassette according to claim 1 .